Articles By Estel Grace Masangkay

  1. Lilly And Boehringer Ingelheim Revise Diabetes Alliance 11/3/2014

    Eli Lilly & Co. with its partner Boehringer Ingelheim announced that the companies have made changes to their diabetes alliance in order to focus more on launching products.

  2. DCVMN International, India Vaccine Manufacturers To Support Vaccine Initiative 11/3/2014

    The Developing Countries Vaccine Manufacturers Network (DCVMN) International has committed to support a $3.6 million program that will aim to deliver high quality and affordable vaccines in India.

  3. Zogenix Acquires Brabant Pharma, Drug Lead For Dravet Syndrome 10/31/2014

    Pharmaceutical company Zogenix announced that it has acquired U.K.-based Brabant Pharma along with global rights to Brabafen (low-dose fenfluramine) for the treatment of Dravet syndrome.

  4. J&J Opens New Innovation Center In China 10/31/2014

    Johnson & Johnson Innovation announced the launch of its new Asia Pacific Innovation Center based in Shanghai with satellite centers in Japan, Singapore, and Australia.

  5. CRUK Enters Agreement To Fund Blood Cancer Trials 10/31/2014

    Cancer Research UK together with its commercial arm Cancer Research Technology announced that it has entered into agreement with Leukemia & Lymphoma Research to fund early stage clinical trials investigating drug candidates for blood cancer.

  6. Novartis Divests Flu Vaccine Business To CSL For $275M 10/30/2014

    Novartis announced that it has agreed to divest its influenza vaccines business to Australian firm CSL Limited, the largest blood products company in the world, for $275 million.

  7. CHMP Backs Roche's IPF Drug Esbriet Label Update 10/30/2014

    Roche reported that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending the label update of its Esbriet (pirfenidone) in the EU.

  8. MediciNova Gets FDA Orphan Status For IPF Drug 10/27/2014

    Biopharmaceutical firm MediciNova announced the U.S. Food and Drug Administration (FDA) designation of MN-001 (tipelukast) as an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

  9. Lilly Expands Oncology Partnership With Zymeworks 10/27/2014

    Eli Lilly & Co. announced that it is expanding its licensing and collaboration agreement with Canadian biotherapeutics firm Zymeworks — a move that could end up making the partnership worth up to $375 million.

  10. FDA Accepts Merck And Sanofi's BLA For Hexavalent Vaccine 10/24/2014

    Merck, together with its partner Sanofi Pasteur, the vaccines division of Sanofi, reported that the U.S. Food and Drug Administration (FDA) has accepted for review the companies’ Biologics License Application (BLA) for the investigational pediatric hexavalent vaccine, DTaP5-IPV-Hib-HepB1.